OR Royalties (NYSE:OR) Rating Lowered to Strong Sell at Zacks Research

OR Royalties (NYSE:ORGet Free Report) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday,Zacks.com reports.

Other research analysts have also recently issued research reports about the company. Scotiabank dropped their price target on OR Royalties from $51.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Tuesday. Weiss Ratings lowered OR Royalties from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 4th. Royal Bank Of Canada lowered their price objective on OR Royalties from $50.00 to $45.00 and set an “outperform” rating on the stock in a research note on Thursday, July 9th. Jefferies Financial Group dropped their price objective on shares of OR Royalties from $40.00 to $34.00 and set a “hold” rating on the stock in a report on Monday, July 6th. Finally, Wall Street Zen downgraded shares of OR Royalties from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.50.

Check Out Our Latest Analysis on OR

OR Royalties Trading Up 0.4%

NYSE:OR opened at $28.86 on Monday. OR Royalties has a 12 month low of $26.86 and a 12 month high of $48.06. The firm’s 50 day moving average is $34.31 and its 200 day moving average is $38.27. The stock has a market capitalization of $5.41 billion, a PE ratio of 21.54 and a beta of 0.74.

OR Royalties (NYSE:ORGet Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The basic materials company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. OR Royalties had a return on equity of 15.10% and a net margin of 78.09%.The business had revenue of $102.83 million during the quarter, compared to analyst estimates of $103.27 million. Research analysts predict that OR Royalties will post 1.35 earnings per share for the current year.

Institutional Trading of OR Royalties

Several institutional investors and hedge funds have recently bought and sold shares of OR. Linden Thomas Advisory Services LLC grew its stake in shares of OR Royalties by 4.1% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 6,254 shares of the basic materials company’s stock valued at $221,000 after buying an additional 249 shares during the last quarter. FCA Corp TX lifted its stake in shares of OR Royalties by 0.8% in the 1st quarter. FCA Corp TX now owns 39,647 shares of the basic materials company’s stock valued at $1,507,000 after acquiring an additional 330 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of OR Royalties by 6.2% in the 4th quarter. Wells Fargo & Company MN now owns 5,901 shares of the basic materials company’s stock valued at $209,000 after acquiring an additional 346 shares during the last quarter. Allworth Financial LP lifted its stake in shares of OR Royalties by 20.0% in the 4th quarter. Allworth Financial LP now owns 2,305 shares of the basic materials company’s stock valued at $82,000 after acquiring an additional 384 shares during the last quarter. Finally, Cetera Investment Advisers boosted its holdings in OR Royalties by 3.5% during the 2nd quarter. Cetera Investment Advisers now owns 13,147 shares of the basic materials company’s stock valued at $337,000 after acquiring an additional 440 shares during the period. 68.52% of the stock is currently owned by hedge funds and other institutional investors.

OR Royalties Company Profile

(Get Free Report)

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.

Further Reading

Analyst Recommendations for OR Royalties (NYSE:OR)

Receive News & Ratings for OR Royalties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OR Royalties and related companies with MarketBeat.com's FREE daily email newsletter.